All In MedTech

FDA Clearance Tracker · P190021-S009

ReActiv8 Implantable Neurostimulation System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 20, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 20, 2025

Approved

Time to decision

87 days

Received Mar 25, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P190021-S009
Device name
ReActiv8 Implantable Neurostimulation System
Applicant location
Swords, Co Dublin
Received
Mar 25, 2025
Decided
Jun 20, 2025
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P190021

Device type

Device class
Class III

Every decision under product code QLK

FDA's approval statement

As written in FDA's record.

approval for labeling updates for the Mainstay ReActiv8 System including: 1) inclusion of 5-year follow-up clinical data in the “Clinical Summary” manual and 2) updates to risks in the “Implant and Programming” manual and the “User Manual”.

Source documents

Other decisions for Mainstay Medical Limited

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.